Journal of Clinical Oncology, Vol 14, 2098-2100, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Malignant mesothelioma following treatment for Hodgkin's disease

LB Weissmann, JM Corson, AI Neugut and KH Antman
Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.

PURPOSE: Asbestos exposure is the major known risk factor for mesothelioma, but several case reports have suggested a link between radiation therapy and subsequent development of malignant mesothelioma. This report explores a possible association between radiation therapy for Hodgkin's disease and mesothelioma. PATIENTS AND METHODS: Four cases of malignant mesothelioma were observed following Hodgkin's disease at the Mesothelioma Clinic of the Dana-Farber Cancer Institute. A fifth such patient was found after a review of the literature. RESULTS: In all five cases, the mesothelioma arose in the field of prior radiotherapy. No history of asbestos exposure was elicited by careful questioning or by review of chest radiographs. Examination of lung tissue in one patient showed 250 ferruginous bodies per gram of lung tissue, consistent with no significant prior exposure. The mean interval between radiation treatment for Hodgkin's disease and development of mesothelioma was 15 years, which emphasizes the need for continued follow-up and evaluation of these patients and supports a causal relationship. CONCLUSION: Mesothelioma may need to be added to the list of second malignancies that arise following radiation therapy for Hodgkin's disease. Further support is given to a causal link between radiation exposure and mesothelioma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. C. Hodgson, E. S. Gilbert, G. M. Dores, S. J. Schonfeld, C. F. Lynch, H. Storm, P. Hall, F. Langmark, E. Pukkala, M. Andersson, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma J. Clin. Oncol., April 20, 2007; 25(12): 1489 - 1497. [Abstract] [Full Text] [PDF]

				P. Das, A. K. Ng, M. A. Stevenson, and P. M. Mauch Clinical course of thoracic cancers in Hodgkin's disease survivors Ann. Onc., May 1, 2005; 16(5): 793 - 797. [Abstract] [Full Text] [PDF]

				Y. Najean and J.-D. Rain Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years Blood, November 1, 1997; 90(9): 3370 - 3377. [Abstract] [Full Text] [PDF]

				J. B. RUBINS, T. GREATENS, R. A. KRATZKE, A. T. TAN, V. A. POLUNOVSKY, and P. BITTERMAN Lovastatin Induces Apoptosis in Malignant Mesothelioma Cells Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1616 - 1622. [Abstract] [Full Text]